Call us 24/7

Clinical trials


35 Clinical Trials

A Phase 2, multi-center, open-label, two-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem]) in patients with unresectable, locally advanced, recurrent or metastatic biliary tract cancer (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer), who are naïve to tumor-directed therapy in the locally advanced or metastatic setting, and for which treatment with 1L therapy (defined as a combination of cis/gem) is planned.

Accepting new patients

The purpose of this study is to determine if the study drug talazoparib (also called BMN 673) is safe when given as a breast cancer treatment and to evaluate how cancer responds to it.

Accepting new patients

This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer.

Accepting new patients

The purpose of this study is to test study treatments that combine an investigational drug (tucatinib, which is also known as ONT-380) (the “study drug”) with two approved drugs (capecitabine and trastuzumab) in participants with advanced breast cancer to find out what effects, good or bad, it may have on the participants and their disease.

The purpose of this study is to determine which treatment regimen is better (margetuximab with standard chemotherapy versus trastuzumab with standard chemotherapy). Survival, tumor size, side effects and quality of life for the two treatments will be compared.

This study will test whether participants with metastatic (having spread to distant organs beyond the breast or close by lymph nodes) or locally-advanced (cancer that hasn’t spread but cannot be cured by surgery) HER2-positive breast cancer that has worsened following standard treatments or lines of therapy will benefit from treatment with standard chemotherapy plus margetuximab compared to standard chemotherapy plus trastuzumab (also called Herceptin®).

This is a multi-national, multi-center, randomized, open-label, parallel group phase III study.

In phase 2, the selected combined dose level of AGEN2034 and AGEN1884, established in part A, will be administered for a maximum of two years or until confirmed progression, unacceptable toxicity, or any criterion for stopping the study drugs or withdrawal from the trial occurs. Cancer Treatment Centers of America® (CTCA) is participating in phase 2, part B: Cervical.

Accepting new patients

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice.

Accepting new patients

The purpose of this trial is to study the effects of the trūFreeze® Spray Cryotherapy System in subjects who have been diagnosed with persistent local esophageal cancer and who are not surgical candidates or have completed or declined systemic therapy.

Accepting new patients

The purpose of this open-label study is to determine the effects of TGR-1202 in patients with relapsed or refractory follicular lymphoma.